Tenaya Therapeutics, Inc. · NASDAQ:TNYA

Tenaya Therapeutics — Technical Presentation (2022)

15 slides from Tenaya Therapeutics's technical presentation, 2022

  1. Slide 1: Cardiac AAV:PKP2 Gene Therapy in a Pkp2-deficient Mouse Model of ARVC

    Cardiac AAV:PKP2 Gene Therapy Reduces Ventricular Arrhythmias, Reverses Adverse Right Ventricular Remodeling, Improves Heart Function, and Extends Survival in a Pkp2-deficient Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy Iris Wu1, Amara Greer-Short1, Aliya Zeng1, Emma Xu1, Melissa

  2. Slide 2: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

    Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) ARVC Symptoms Disease Progression Age Group Early arrhythmias Concealed • Presents in young • Palpitations, Phase adults • Lightheadedness • Average < 40 • Syncope (fainting) Ventricular years old Arrythmia Progressive development • Important ca

  3. Slide 3: Current Therapy for ARVC

    Current Therapy for ARVC No Therapies Address the Underlying Genetic Cause of Disease to Prevent Onset and Prevent Progression New Treatment Standard of Care Limitations of Care Paradigm Needed Anti-Arrhythmic • Not fully effective Medications • Side effects Options to prevent • Potential for compli

  4. Slide 4: Majority of ARVC Caused by Desmosome Mutations

    Majority of ARVC Caused by Desmosome Mutations Desmosomes Zip Heart Cells Together and Support Gap PKP2 Mutations are the Predominant Junctions to Maintain Electrical Coupling Genetic Cause of ARVC PKG Desmoplakin Cx43 • Autosomal dominant inheritance Plakophilin 2 Connexin 43 • ~70K patients with P

  5. Slide 5: PKP2 Mutation is Associated with Reduction of Protein Levels and Loss of Desmosome Structure

    PKP2 Mutation is Associated with Reduction of Protein Levels and Loss of Desmosome Structure in Human Hearts Loss of Desmosomes in PKP2-mutated Human Heart PKP2 DSP PKG Cx43 Control PKP2 Cx43 mutated Asimaki et al. (2009) NEJM 5

  6. Slide 6: Potential to Use AAV Gene Therapy for ARVC Due to PKP2 Mutations

    Potential to Use AAV Gene Therapy for ARVC Due to PKP2 Mutations TN-401 is a Gene Therapy to Restore the Expression and Function of PKP2 in the Heart Vector = Adeno-Associated Virus (AAV) • AAVs are naturally-occurring viruses that do not cause disease Promoter = Cardiac-specific X Gene: PKP2 Expres

  7. Slide 7: Increasing Use of AAV Gene Therapy

    Increasing Use of AAV Gene Therapy Approved Gene Therapy Number of Clinical Studies Using AAV, by Start Year Products >1,800 patients treated >3,000 patients treated in ~150 AAV gene therapy studies1 in >40 countries2 1 Modified from Kuzmin et al., NatRevDrugDiscov 2021 2 Novartis corporate press re

  8. Slide 8: Cardiac-specific Pkp2 Knockout Mouse Model Recapitulates Human ARVC Phenotypes

    Cardiac-specific Pkp2 Knockout Mouse Model Recapitulates Human ARVC Phenotypes Premature Mortality Decreased LV Ejection Fraction Increased Spontaneous PVCs Life Span Week Post Induction Animal Cardiac 80 100 n=4 Week1 Week2 Week3 Function n=4 n=4 n=4 n=4 Ejection Fraction (%) Probability of Surviva

  9. Slide 9: Single Dose Cardiac AAV:PKP2 Gene Therapy Reduces Ventricular Arrhythmias

    Single Dose Cardiac AAV:PKP2 Gene Therapy Reduces Ventricular Arrhythmias WT: Normal Sinus Rhythm Control: Abnormal Ventricular Beats (NSVT & PVCs) Reduced amplitude Gene Therapy: Normal Sinus Rhythm NSVT= Non-sustained ventricular tachycardia AV = Atrioventricular 9

  10. Slide 10: Single Dose Gene Therapy Demonstrates Disease Modification and Survival Benefit

    Single Dose Cardiac AAV:PKP2 Gene Therapy Demonstrates Disease Modification and Survival Benefit Prevention of Right Prevention of Decline Extension of Life Span Ventricle Enlargement of Left Ventricle Function WT 100 Control Gene Therapy <0.0001 0.20 Ejection Fraction (%) 100 80 Probability of Surv

  11. Slide 11: Single Dose Gene Therapy Restores Desmosomes and Gap Junctions

    Single Dose Cardiac AAV:PKP2 Gene Therapy Restores Desmosomes and Gap Junctions WT PKP2 2 DSP Control Relative Protein Expression 4 Dose 1 Dose 2 Gene Therapy Desmosome 3 Dose 3 Protein 2 1 Expression 1 0 0 WT Control Gene Therapy Cx43 IHC at Gap Junction 11

  12. Slide 12: Single Dose Gene Therapy Prevents Fibrosis

    Single Dose Cardiac AAV:PKP2 Gene Therapy Prevents Fibrosis WT Control Gene Therapy 15 10 % Collagen Trichrome Staining 5 0 WT Control Gene Therapy Yellow arrows = Fibrosis 12

  13. Slide 13: Summary

    Summary  Preclinical results using a cardiac-specific Pkp2 knockout mouse model provide encouraging evidence that cardiac AAV:PKP2 gene therapy may be a promising therapeutic option for ARVC patients with PKP2 mutations Cardiac AAV:PKP2 gene therapy in a mouse model • Reduces ventricular arrhythmia

  14. Slide 14: Encouraging Genetic Testing and Partnering with ARVC Experts

    • To further advance the development of genetic medicines for inherited cardiovascular disease, we encourage genetic testing • Per HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies (2011) • Genetic testing for ARVC is increasingly availa

  15. Slide 15: Thank you

    Thank you We thank Dr. Mario Delmar and NYU for licensing Pkp2-cKO mouse

Tenaya Therapeutics — Technical Presentation (2022) on 6ix